co plc
news dcb safeti support pcr statement
kstew live europcr
dear client appreci consider institut investor all-america all-canada research survey view
analyst pleas click
bon jour pari
 attend annual europcr confer hich held pari franc ant pass along favor
new drug-coat balloon dcb remind tw leader dcb market
 ith million sale repres total compani sale respect
session today pcr discuss favor view statement clinic outcom intervent ith paclitaxel drug-
coat balloon dcb see link view new support safeti profil dcb rate
overw eight last eek upgrad overw eight see note reset outlook valuat provid longer term opportun upgrad
ow date link base view stock recent pullback reset expect follow ing result
provid opportun investor view overreact dcb new flow believ upcom
fda committe meet june like provid greater clariti calm dcb concern today new reaffirm view
 ere tw key passag pcr statement
statement emphas addit evid individu sponsor-driven patient-level analys clinic trial data well
large-scal claim data fail replic result meta-analysi respect associ paclitaxel exposur
long-term mortal furtherm ore safeti signal ev er shown coronari dcb applic long-term
pend av ailabl ore conclusiv data current strong ev idenc justifi chang clinic practic
clinician continu use best judgm ent use paclitaxel-bas dcb
 believ statement help calm nervous around dcb european market also believ
reduc likelihood unfavor outcom upcom fda advisori committe meet june said believ
anoth fda statement like need revers recent declin us sale ow ing fda march statement
feel free reach ith question happi chat best ay reach via email
 commentari
dcb session said
session dr alexandra lanski intervent cardiologist cardiologist yale univers school medicin review ed
meta-analysi start hat session introduct refer storm tea cup note limit
meta-analysi present slide illustr patient pool analysi
four random clinic trial thunder fempac pacifi consequ ith year outcom show ing differ
medtron pact pool patient level analysi show ing statist increas death betw een pact group versu
regular pta show ing paclitaxel dose per patient predict mortal
levant studi hich show ed statist increas rate mortal betw een lutonix
dcb pta recent earn call becton note third parti review patient level data result
continu support safeti lutonix bd manag expect find publish journal
philip stellarex pool random data also show ing statist increas mortal betw een stellarex dcb pta
claim data consist patient ith femoroplit revascular ith drug coat devic versu non-drug
coat devic show ing differ adjust surviv
meta-analysi katsano analysi major inher methodolog limit prevent reliabl interpret
primari find includ study-level versu patient-level data limit long-term data unmeasur
crossov re-intervent unknow addit paclitaxel exposur lack adjud caus death error
publish death rate ith subsequ correct lack plausibl reproduc dose respons
least new patient level analys large-scal claim data analysi fail replic result meta-analysi
current strong evid mortal signal
drug-coat balloon dcb incorpor drug paclitaxel use peripher vascular intervent show
clinic improv tradit percutan translumin angioplasti pta balloon tw
leader dcb market ith million sale repres total compani sale respect
decemb meta-analysi publish journal american heart associ see link titl risk death
follow ing applic paclitaxel coat balloon stent femoropoplit arteri systemat review
meta analysi random control trial articl conclud increas risk death follow applic
paclitaxel coat balloon stent femoropoplit arteri lower limb investig urgent warrant
follow ing aha journal public sever medic societi announc ould also look safeti concern
januari fda issu letter physician see link acknow ledg meta-analysi note ould look
data time fda comment fda believ benefit continu outweigh risk approv paclitaxel-
coat balloon paclitaxel-elut stent use accord indic use letter prompt physician
begin rethink decis make hether use dcb
sever industri medic societi physician eigh dcb concern note potenti signal data march
fda issu updat notif see link healthcar profession note preliminari review data
identifi potenti concern signal increas long-term mortal patient ho receiv paclitaxel-co product
specif fda review ed long-term follow -up data pivot pre-market random trial paclitaxel-co product indic
pad accord fda three trial ith follow -up data show ed approxim higher risk mortal
subject treat ith paclitaxel-co product subject treat ith uncoat devic versu crude risk
death year fda note data interpret ith caution given larg variabl risk estim
mortal due limit amount long-term data studi ere origin design pool introduc greater
uncertainti result specif caus mechan increas mortal unknow fda recommend
light analysi patient altern treatment option paclitaxel-co balloon paclitaxel-elut stent
gener use addit analysi safeti signal perform individu patient particularli high risk
restenosi clinician may determin benefit use paclitaxel-co product may outweigh risk
fda ill conven meet circulatori devic panel june make recommend base observ
increas long-term mortal patient treat ith paclitaxel-co product compar uncoat devic see event link
fda request panel input regard presenc magnitud signal potenti caus fda also seek input
regard appropri regulatori action associ ith find fda plan make background materi avail
public later busi day meet
earn call may bd manag note ork ith third parti review lutonix data
increas confid safeti profil product note third parti find ere expect publish
medic journal ould expect compani submit find review fda advisori meet thu view
believ data ultim eas market concern expect lutonix remov market
view low probabl event
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
co usd overw eight/posit cd/ce/d/e/j/k/l/m/n
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor
extent becton success integr bard see greater expect revenue/cost synergi nside fx
stronger us dollar commod cost could greater headw ind risk factor includ time success new
product increas competit key product drug-coat balloon infus pump signific chang
reimburs fda govern action
rate price target histori
co
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog believ
share trade line ith histor averag price target appli target pe calendar ep estim
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook upsid greater success ith new product margin expans risk includ signific reimburs chang
competit pressur product failur fda govern action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
